Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718409 | 0.85 | THRB (0.43) | MAPTRAB9ARXFP1TP53KDM4E | |
| SCHEMBL6718675 | 0.85 | MAPT (0.51) | MAPTRAB9APPARGTRPA1RXFP1 | |
| SCHEMBL6678339 | 0.83 | MAPT (0.51) | MAPTRAB9APPARGTRPA1RXFP1 | |
| SCHEMBL6680635 | 0.79 | TRPA1 (0.41) | RAB9ATRPA1TP53LMNA | |
| SCHEMBL6683536 | 0.76 | TRPA1 (0.45) | MAPTPPARGTRPA1TP53POLB | |
| SCHEMBL5957675 | 0.75 | TRPA1 (0.79) | MAPTRAB9ATRPA1NR3C2TP53 | |
| SCHEMBL6681435 | 0.73 | THRB (0.43) | MAPTRAB9ARXFP1TP53KDM4E | |
| SCHEMBL6664200 | 0.73 | MAPT (0.47) | MAPTRAB9ARXFP1MMP13NR3C2 | |
| SCHEMBL6665653 | 0.72 | MMP1 (0.43) | MAPTRAB9ARXFP1TP53KDM4E | |
| SCHEMBL6685134 | 0.72 | MAPT (0.49) | MAPTRAB9ARXFP1MMP13NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | claimed |
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2004014354-A1 | 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP11 | MAPT 1535/4885RAB9A 672/4885PPARG 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.